Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000531703 | SCV000623360 | uncertain significance | Bloom syndrome | 2024-11-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 33 of the BLM protein (p.Ser33Leu). This variant is present in population databases (rs139282091, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 133703). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000568835 | SCV000672942 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-02 | criteria provided, single submitter | clinical testing | The p.S33L variant (also known as c.98C>T), located in coding exon 1 of the BLM gene, results from a C to T substitution at nucleotide position 98. The amino acid change results in serine to leucine at codon 33, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Institute for Clinical Genetics, |
RCV003237720 | SCV002010744 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003237720 | SCV004222514 | uncertain significance | not provided | 2023-08-16 | criteria provided, single submitter | clinical testing | In the published literature, this variant has been reported in unaffected individuals (PMID: 24728327 (20104)). The frequency of this variant in the general population, 0.000027 (7/262566 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. |
ITMI | RCV000120232 | SCV000084379 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Natera, |
RCV000531703 | SCV002089883 | uncertain significance | Bloom syndrome | 2018-11-17 | no assertion criteria provided | clinical testing |